Abstract
The number of patients living with diabetes has increased significantly in recent years due to several factors. Many of these patients are choosing to use insulin pumps for their treatment, artificial systems that administer their insulin and consist of a glucometer and an automatic insulin supply working in an open loop. Currently, only a few closed-loop insulin delivery devices are commercially available. The most widespread systems among patients are what have been called the “Do-It-Yourself Hybrid Closed-Loop systems.” These systems require the use of platforms with high computing power. In this paper, we will present a novel wearable system for insulin delivery that reduces the energy and computing consumption of the platform without affecting the computation requirements. Patients’ information is obtained from a commercial continuous glucose sensor and a commercial insulin pump operating in a conventional manner. An ad-hoc embedded system will connect with the pump and the sensor to collect the glucose data and process it. That connection is accomplished through a radiofrequency channel that provides a suitable system for the patient. Thus, this system does not require to be connected to any other processor, which increases the overall stability. Using parameters configured by the patient, the control system will make automatic adjustments in the basal insulin infusion thereby bringing the patient’s glycaemia to the target set by a doctor’s prescription. The results obtained will be satisfactory as long as the configured parameters faithfully match the specific characteristics of the patient. Results from the simulation of 30 virtual patients (10 adolescents, 10 adults, and 10 children), using a python implementation of the FDA-approved (Food and Drug Administration) UVa (University of Virginia)/Padova Simulator and a python implementation of the proposed algorithm, are presented.
Highlights
Diabetes is a condition that affected approximately a 10% of the population during 2015 [1].Even though there are many subdivisions of diabetes types, like LADA, new-born diabetes, etc., it is still generally accepted the three general categories of type 1, type 2, and gestational
Current commercial insulin pumps are designed to work in open loop mode, they operate in a way that meets the needs for the patients in this situation: insulin pumps allow insulin
If users need to modify their basal infusion for a reduced period of time. This basal profile selection is normally done in a insulin pump will be suitable for a closed-loop insulin delivery system if it can be controlled by an hours)
Summary
Diabetes is a condition that affected approximately a 10% of the population during 2015 [1]. There is no problem reducing the amount of insulin being dosed as the patient or the system can always increase it later, but once insulin has been dosed the system has no way to remove it from the patient’s body This is the main reason why manufacturers are developing these functions by stages; current devices allow what they call as “suspend-on-low”: the insulin pump will suspend the infusion when patient’s glycaemia is, or is predicted to be, below a certain security threshold. Other works [9,10] address solutions more complex that do not focus on a wearable approach What all of these systems have in common is that they use glucose and insulin dosing information to calculate the actions needed to keep the patient in a defined range (configurable or not by the user).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
